565 related articles for article (PubMed ID: 17848653)
21. Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.
Mendes D; Alves C; Batel-Marques F
Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1259-70. PubMed ID: 26376779
[TBL] [Abstract][Full Text] [Related]
22. Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.
Chen X; Yang L; Zhai SD
Chin Med J (Engl); 2012 Dec; 125(23):4301-6. PubMed ID: 23217404
[TBL] [Abstract][Full Text] [Related]
23. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
Liao HW; Saver JL; Wu YL; Chen TH; Lee M; Ovbiagele B
BMJ Open; 2017 Jan; 7(1):e013927. PubMed ID: 28057658
[TBL] [Abstract][Full Text] [Related]
24. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
Loke YK; Kwok CS; Singh S
BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101
[TBL] [Abstract][Full Text] [Related]
25. Results of a reevaluation of cardiovascular outcomes in the RECORD trial.
Mahaffey KW; Hafley G; Dickerson S; Burns S; Tourt-Uhlig S; White J; Newby LK; Komajda M; McMurray J; Bigelow R; Home PD; Lopes RD
Am Heart J; 2013 Aug; 166(2):240-249.e1. PubMed ID: 23895806
[TBL] [Abstract][Full Text] [Related]
26. The rough road for rosiglitazone.
Goldfine AB
Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
[TBL] [Abstract][Full Text] [Related]
27. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
Circulation; 2013 Aug; 128(8):785-94. PubMed ID: 23857320
[TBL] [Abstract][Full Text] [Related]
28. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
29. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.
Bourg CA; Phillips BB
Ann Pharmacother; 2012 Feb; 46(2):282-9. PubMed ID: 22298606
[TBL] [Abstract][Full Text] [Related]
30. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.
Diamond GA; Bax L; Kaul S
Ann Intern Med; 2007 Oct; 147(8):578-81. PubMed ID: 17679700
[TBL] [Abstract][Full Text] [Related]
31. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
Lago RM; Singh PP; Nesto RW
Lancet; 2007 Sep; 370(9593):1129-36. PubMed ID: 17905165
[TBL] [Abstract][Full Text] [Related]
32. Rosiglitazone for type 2 diabetes mellitus.
Richter B; Bandeira-Echtler E; Bergerhoff K; Clar C; Ebrahim SH
Cochrane Database Syst Rev; 2007 Jul; 2007(3):CD006063. PubMed ID: 17636824
[TBL] [Abstract][Full Text] [Related]
33. Rosiglitazone and cardiovascular risk.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
[No Abstract] [Full Text] [Related]
34. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
35. Effects on All-cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-analysis of Randomized Controlled Trials.
Li J; Tong Y; Zhang Y; Tang L; Lv Q; Zhang F; Hu R; Tong N
Clin Ther; 2016 Feb; 38(2):372-386.e6. PubMed ID: 26774276
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
37. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Singh S; Loke YK; Furberg CD
JAMA; 2008 Sep; 300(12):1439-50. PubMed ID: 18812535
[TBL] [Abstract][Full Text] [Related]
38. Rosiglitazone and cardiovascular risk: weighing recent evidence.
Stafylas PC; Sarafidis PA; Lasaridis AN
J Cardiometab Syndr; 2007; 2(4):295-6. PubMed ID: 18059214
[No Abstract] [Full Text] [Related]
39. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.
Castagno D; Baird-Gunning J; Jhund PS; Biondi-Zoccai G; MacDonald MR; Petrie MC; Gaita F; McMurray JJ
Am Heart J; 2011 Nov; 162(5):938-948.e2. PubMed ID: 22093212
[TBL] [Abstract][Full Text] [Related]
40. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
Winkelmayer WC; Setoguchi S; Levin R; Solomon DH
Arch Intern Med; 2008 Nov; 168(21):2368-75. PubMed ID: 19029503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
